Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun;20(6):347-348.
doi: 10.1038/s41577-020-0323-4. Epub 2020 Apr 28.

COVID-19 vaccine design: the Janus face of immune enhancement

Peter J Hotez  1   2   3   4 , David B Corry  5   6 , Maria Elena Bottazzi  7   8   9
Affiliations

COVID-19 vaccine design: the Janus face of immune enhancement

Peter J Hotez et al. Nat Rev Immunol. 2020 Jun.

Abstract

Previous work on severe acute respiratory syndrome coronavirus (SARS-CoV) vaccines identified cellular immunopathology and antibody-dependent enhancement as potential safety issues. We discuss the implications of these findings for COVID-19 vaccine development and our approach to optimizing for safety and efficacy.

PubMed Disclaimer

Conflict of interest statement

P.J.H. and M.E.B. are investigators leading the development of coronavirus vaccines against SARS-CoV, MERS-CoV and SARS-CoV-2. D.B.C. is a scientific advisor and holds intellectual property in Atropos Therapeutics, LLC.

Figures

None
Janus, the two-headed Roman god of doors and beginnings. Science History Images/Alamy
See this image and copyright information in PMC

References

    1. Thanh Le T, et al. The COVID-19 vaccine development landscape. Nat. Rev. Drug Discov. 2020 doi: 10.1038/d41573-020-00073-5. - DOI - PubMed
    1. Cao Z, et al. Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients. Virol. J. 2010;7:299. doi: 10.1186/1743-422X-7-299. - DOI - PMC - PubMed
    1. Hotez PJ, Bottazzi ME. Developing a low-cost and accessible COVID-19 vaccine for global health. Preprints. 2020;2020:2020030464. - PMC - PubMed
    1. Tai W, et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell. Mol. Immunol. 2020 doi: 10.1038/s41423-020-0400-4. - DOI - PMC - PubMed
    1. Tseng C-T, et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS One. 2012;7:e35421. doi: 10.1371/journal.pone.0035421. - DOI - PMC - PubMed